Research programme: acetylcholinesterase - Protalix Biotherapeutics

Drug Profile

Research programme: acetylcholinesterase - Protalix Biotherapeutics

Alternative Names: AChE programme - Protalix Biotherapeutics

Latest Information Update: 12 Mar 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boyce Thompson Institute for Plant Research; Hebrew University of Jerusalem
  • Developer Protalix Biotherapeutics
  • Class Antitoxins; Recombinant proteins
  • Mechanism of Action Cholinesterase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Poisoning

Most Recent Events

  • 07 Mar 2012 No development reported - Preclinical for Poisoning in Israel (Parenteral)
  • 22 Jan 2008 Protalix Biotherapeutics extends its research agreement with Yissum Research Development Company to include a collaborative research programme at the Hebrew University of Jerusalem
  • 22 Jan 2008 Preclinical trials in Poisoning in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top